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Introduction
HIV-protease inhibitors may increase tenofovir
plasma AUC by 22-37%. Whether this affects
tenofovir-diphosphate (TFV-DP) intracellular levels,
especially in the presence of didanosine, which is also
eliminated through active tubular secretion, is unclear.
Case report
A 52-year-old HIV-1 positive Caucasian male started
zidovudine (AZT), lamivudine, nelfinavir in 1999 at a
CD4-cell count of 210/µL. In July 2007 treatment was
switched because of viral blips to atazanavir, ritonavir,
tenofovir, emtricitabine and didanosine (250 mg).
Within one year his CD4-cell count declined from 1140
to 140/µL despite complete virological suppression [1].
Renal clearance (Cockgroft-Gault) decreased from 86 to
74 mL/min and renal phosphate threshold to 0.24
mmol/L (n=0.8-1.35), indicative of proximal tubular dys-
function. There was 8 kg weight loss, his serum glucose
and lactate were elevated.
In addition, following the ART-switch a thrombocyto-
sis (1355x10
9/L) was noticed. After exclusion of other
causes, essential thrombocythemia was diagnosed and
hydroxyurea started. Thrombocytes were elevated before
initiation of ART (427x10
9/L) and before therapy switch
(659x10
9/L), suggesting AZT-related bone marrow sup-
pression may have prevented a further increase in platelet
count in the preceding years.
Suspecting NRTI-related mitochondrial and tubular dys-
function, we measured intracellular ddA-TP (didanosine)
and TFV-DP (tenofovir) in PBMCs [2]. TFV-DP was
10xULN (1350 fmol/10
6 cells) and ddA-TP 21xULN
(105 fmol/10
6 cells). Hydroxyurea may have increased
ddA-TP levels, but was used for only 2 weeks. ART was
changed to AZT, lamivudine, atazanavir, ritonavir, ralte-
gravir. Two weeks later TFV-DP was still 250 fmol/10
6
cells, demonstrating an intracellular t½ of approximately
140 hrs and ddA-TP 57.4 fmol/10
6cells, t½ 385 hrs, but
didanosine and tenofovir plasma levels were undetectable.
After switch his CD4-cell count increased again from 140
to 340/µL and his platelet count decreased to 725x10
9/L
following re-initiation of AZT.
Conclusions
Elevated TFV-DP and ddA-TP led to tubular dysfunction
and mitochondrial toxicity. Inhibition of purine-nucleo-
side-phosphorylase by TFV-DP and DNA-polymerase-g by
ddA-TP may have caused the steep CD4-cell decline. We
believe interactions between tenofovir, didanosine and ata-
zanavir/ritonavir were responsible for this toxicity.
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